Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2021

01-09-2021 | Multiple Myeloma | review

Multiple myeloma: my highlights at ASH 2020

Author: Eberhard Gunsilius

Published in: memo - Magazine of European Medical Oncology | Issue 3/2021

Login to get access

Summary

The meeting focused in particular on new strategies such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies. Updates of clinical trials regarding induction treatment in transplantable and non-transplantable status were presented. Furthermore, minimal residual disease negativity (MRD) or, in other words, a status characterized by no measurable disease, using standardized multicolor-flow cytometry or next-generation sequencing techniques becomes increasingly important as an endpoint in clinical trials. A subjectively assessed overview of the current contributions to the treatment of multiple myeloma is given here.
Literature
1.
Kaufman JL, Laubach JP, Sborov D, Reeves B, Rodriguez C, Chari A, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of griffin after 12 months of maintenance therapy. Blood. 2020;136(Supplement 1):45–6.CrossRef
2.
Gay F, Musto P, Rota Scalabrini D, Galli M, Belotti A, Zamagni E, et al. Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized forte trial. Blood. 2020;136(Supplement 1):35–7.CrossRef
3.
Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136(Supplement 1):39–39.CrossRef
4.
Cavo M, Gay F, Beksac M, Dimopoulos MA, Pantani L, Petrucci MT, et al. Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: long-term follow-up analysis of the randomized phase 3 EMN02/HO95 study. Blood. 2020;136(Supplement 1):37–8.CrossRef
5.
Kumar SK, Facon T, Usmani SZ, Plesner T, Orlowski RZ, Touzeau C, et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-rd) versus lenalidomide and dexamethasone (rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia study. Blood. 2020;136(Supplement 1):24–6.CrossRef
6.
Facon T, et al. The phase 3 TOURMALINE-MM2 trial: oral Ixazomib, Lenalidomide, and Dexamethasone (Ird) vs placebo-rd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). In: ASH 2020, virtual edition, abstract 551. 2020.
7.
Rodriguez-Otero P, Boccadoro M, Hajek R, Fujisaki T, Lee JH, Martinez-Lopez J, et al. Long-term outcomes and health-related quality of life (HRQoL) by response status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in alcyone. Blood. 2020;136(Supplement 1):43–4.CrossRef
8.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Apollo: phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):5–6.CrossRef
9.
Siegel DS, Schiller GJ, Samaras CJ, Sebag M, Berdeja JG, Ganguly S, et al. Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide treatment in relapsed refractory multiple myeloma: updated results from an open-label, multicenter, phase 2 trial. Blood. 2020;136(Supplement 1):16–7.CrossRef
10.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–107.CrossRef
11.
Dimopoulos MA, Quach H, Mateos M‑V, Landgren O, Leleu X, Siegel DS, et al. Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone in relapsed or refractory multiple myeloma: updated efficacy and safety results of the phase 3 candor study. Blood. 2020;136(Supplement 1):26–7.CrossRef
12.
Moreau P, et al. Isatuximab plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study. In: ASH 2020, virtual edition, abstract 2316. 2020.
13.
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood. 2020;136(Supplement 1):26–7.
14.
Garfall AL, Usmani SZ, Mateos M‑V, Nahi H, van de Donk NWCJ, San-Miguel JF, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):27–27.CrossRef
Metadata
Title
Multiple myeloma: my highlights at ASH 2020
Author
Eberhard Gunsilius
Publication date
01-09-2021
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00746-w

Other articles of this Issue 3/2021

memo - Magazine of European Medical Oncology 3/2021 Go to the issue

short review

Rehabilitation for children and adolescents after cancer: importance and implementation in Austria

original report

Effect of the ABO blood groups on the development, clinical features and survival of multiple myeloma

editorial

Interesting news from the annual meeting of the American Society of Hematology 2020

short review

Therapy concepts in the context of precision medicine for pediatric malignancies—children are not adults

short review

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

case report

Decision making in hematology—chronic myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits